drugset / Trial / NCT05905887
Rivoceranib Plus Paclitaxel in Patients With Gastrointestinal Stromal Tumor
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the efficacy and safety of rivoceranib and paclitaxel combination therapy in patients with P-glycoprotein overexpressing GIST who failed standard treatment with imatinib, sunitinib, and regorafenib.
Timeline
- Start
- 2023-09-06
- Primary completion
- 2027-08-31
- Completion
- 2027-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Paclitaxel | Small molecule | 80 mg/m2 | — |
| Subject | Rivoceranib | Small molecule | 400 mg | Oral |